Phase Forward Customer GlaxoSmithKline Signs Multi-Year Agreements
WALTHAM, Mass.–(BUSINESS WIRE)–Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that GlaxoSmithKline (GSK) has signed multi-year, multi-million dollar contracts covering Licensing and Study Support Services. GSK and Phase Forward also have a multi-year agreement in place for hosting services. Under the terms of the newly signed agreements, GSK will continue to utilize Phase Forward’s InForm™ Integrated Trial Management (ITM) solution. Since 2004, GSK has initiated nearly 600 clinical trials with Phase Forward’s InForm electronic data capture solution and utilizing Phase Forward’s hosting and study support services.
“GSK is pleased to have reached an agreement with Phase Forward that will allow us to continue to enjoy the significant efficiency gains we have realized from the use of InForm and associated services over the past five years,” said Diane Fuell, Vice President of Business Support in the Centre for Clinical Study Excellence Operations and Data Quality at GSK. “We will continue to work with Phase Forward to ensure GSK fully benefits from InForm’s capabilities.”
“GSK and Phase Forward share the vision that technology plays a central role in optimizing the global pharmaceutical development process,” said Bob Weiler, chairman and CEO of Phase Forward. “We are enormously proud of the results our work with GSK has achieved to date and look forward to furthering that success in our continued collaboration.”
About GSK
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
